RESUMEN
Nutritional deficiency is a common medical problem that affects 15-40% of cancer patients. It negatively impacts their quality of life and can compromise treatment completion. Oncological therapies, such as surgery, radiation therapy, and drug therapies are improving survival rates. However, all these treatments can play a role in the development of malnutrition and/or metabolic alterations in cancer patients, induced by the tumor or by its treatment. Nutritional assessment of cancer patients is necessary at the time of diagnosis and throughout treatment, so as to detect nutritional deficiencies. The Patient-Generated Subjective Global Assessment method is the most widely used tool that also evaluates nutritional requirements. In this guideline, we will review the indications of nutritional interventions as well as artificial nutrition in general and according to the type of treatment (radiotherapy, surgery, or systemic therapy), or palliative care. Likewise, pharmacological agents and pharmaconutrients will be reviewed in addition to the role of regular physical activity
No disponible
Asunto(s)
Humanos , Neoplasias/dietoterapia , Trastornos Nutricionales/dietoterapia , Terapia Nutricional/métodos , Necesidades Nutricionales , Pautas de la Práctica en Medicina , Desnutrición/dietoterapia , Desnutrición/epidemiología , Evaluación Nutricional , Estado Nutricional , Cuidados Paliativos/métodosRESUMEN
One of the most common side effects of cancer treatment is cardiovascular disease, which substantially impacts long-term survivor's prognosis. Cardiotoxicity can be related with either a direct side effect of antitumor therapies or an accelerated development of cardiovascular diseases in the presence of preexisting risk factors. Even though it is widely recognized as an alarming clinical problem, scientific evidence is scarce in the management of these complications in cancer patients. Consequently, current recommendations are based on expert consensus. This Guideline represents SEOM's ongoing commitment to progressing and improving supportive care for cancer patients
No disponible
Asunto(s)
Humanos , Antineoplásicos/efectos adversos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/diagnóstico , Cardiotoxicidad/diagnóstico , Protocolos Antineoplásicos , Diagnóstico Precoz , Factores de Riesgo , Pruebas de Toxicidad/métodos , Pautas de la Práctica en MedicinaRESUMEN
Purpose. The SEOM Future Plan is aimed at identifying the main challenges, trends and needs of the medical oncology speciality over the next years, including potential oncologist workforce shortages, and proposing recommendations to overcome them. Methods. The estimations of the required medical oncologists workforce are based on an updated Medical Oncologist Register in Spain, Medical Oncology Departments activity data, dedication times and projected cancer incidence. Challenges, needs and future recommendations were drawn from an opinion survey and an advisory board. Results. A shortage of 211 FTE medical oncologist specialists has been established. To maintain an optimal ratio of 158 new cases/FTE, medical oncology workforce should reach 1881 FTE by 2035. Conclusions. Main recommendations to face the growing demand and complexity of oncology services include a yearly growth of 2.5% of medical oncologists workforce until 2035, and development and application of more accurate quality indicators for cancer care and health outcomes measure (AU)
No disponible
Asunto(s)
Humanos , Masculino , Femenino , Oncología Médica , Oncología Médica/organización & administración , Sociedades Médicas/organización & administración , Sociedades Médicas/normas , Servicio de Oncología en Hospital/organización & administración , Servicio de Oncología en Hospital/normas , Oncología Médica/ética , Oncología Médica/normas , Sociedades Médicas/ética , EspañaRESUMEN
Purpose. The Spanish Society of Medical Oncology (SEOM) has conducted a study on the access to oncologic drugs across the 17 Spanish Regions with the aim of identifying potential heterogeneities and making proposals for eliminating the barriers identified at the different levels. Methods. An Expert Panel made up of medical oncologists designed a survey on certain indications approved for 11 drugs in the approach of breast cancer, melanoma, lung cancer, prostate cancer and support treatment. This survey was sent to 144 National Health System (NHS) hospitals. Results. 77 hospitals answered the survey. The information modules analysed were: scope of the Commission that establishes binding decisions related to drug access; conditions, stages and periods of drug application, approval and administration processes; barriers to accessing drugs. Conclusions. The study shows variability in drug access. The SEOM makes proposals addressed to reducing the differences identified and homogenizing drug access conditions (AU)
No disponible
Asunto(s)
Humanos , Masculino , Femenino , Antineoplásicos/administración & dosificación , Antineoplásicos/uso terapéutico , Servicio de Oncología en Hospital/normas , Sociedades Médicas/organización & administración , Sociedades Médicas/normas , Sistemas de Salud/organización & administración , Sistemas de Salud/normas , Instituciones Oncológicas/organización & administración , Instituciones Oncológicas/normas , Disparidades en el Estado de Salud , Disparidades en el Estado de Salud , Encuestas y Cuestionarios/normas , Encuestas y Cuestionarios , Antineoplásicos/análisisRESUMEN
Bone metastases are common in many advanced solid tumours, being breast, prostate, thyroid, lung, and renal cancer the most prevalent. Bone metastases can produce skeletal-related events (SREs), defined as pathological fracture, spinal cord compression, need of bone irradiation or need of bone surgery, and hypercalcaemia. Patients with bone metastases experience pain, functional impairment and have a negative impact on their quality of life. Several imaging techniques are available for diagnosis of this disease. Bone-targeted therapies include zoledronic acid, a potent biphosfonate, and denosumab, an anti-RANKL monoclonal antibody. Both reduce the risk and/or delay the development of SREs in several types of tumours. Radium 233, an alpha-particle emitter, increases overall survival in patients with bone metastases from resistant castration prostate cancer. Multidisciplinary approach is essential and bone surgery and radiotherapy should be integrated in the treatment of bone metastases when necessary. This SEOM Guideline reviews bone metastases pathogenesis, clinical presentations, lab tests, imaging techniques for diagnosis and response assessment, bone-targeted agents, and local therapies, as radiation and surgery, and establishes recommendations for the management of patients with metastases to bone (AU)
No disponible
Asunto(s)
Humanos , Masculino , Femenino , Neoplasias Óseas/complicaciones , Neoplasias Óseas/diagnóstico , Metástasis de la Neoplasia/prevención & control , Metástasis de la Neoplasia/fisiopatología , Metástasis de la Neoplasia , Difosfonatos/uso terapéutico , Denosumab/uso terapéutico , Biomarcadores de Tumor/análisis , Tomografía Computarizada de Emisión de Fotón Único/métodos , Huesos/patología , HuesosRESUMEN
Chemotherapy-induced nausea and vomiting is one of the most worrisome adverse effects of chemotherapy for cancer patients. It can cause severe discomfort and affect the quality of life. In recent years, the incorporation of new drugs has increased the efficacy of antiemetic treatments in the control of emesis associated with chemotherapy. This guideline, in which we give some treatment recommendations with level of evidence and grade of recommendation, provides an update of the previously published guideline of the Spanish Society of Medical Oncology and represents our continued commitment to improving supportive care in cancer patients (AU)
No disponible
Asunto(s)
Humanos , Masculino , Femenino , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/complicaciones , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/prevención & control , Náusea/complicaciones , Náusea/prevención & control , Calidad de Vida , Antieméticos/uso terapéutico , Profilaxis Posexposición/normas , Profilaxis Pre-Exposición/normas , Profilaxis Pre-ExposiciónRESUMEN
Metastatic breast cancer is essentially an incurable disease. However, recent advances have resulted in a significant improvement of overall survival. The SEOM guidelines are intended to make evidence-based recommendations on how to manage patients with metastatic breast cancer to achieve the best patient outcomes based on a rational use of the currently available therapies. To assign a level of certainty and a grade of recommendation the United States Preventive Services Task Force guidelines methodology was selected as reference (AU)
No disponible
Asunto(s)
Humanos , Femenino , /normas , Neoplasias de la Mama/metabolismo , Neoplasias de la Mama/patología , Metástasis de la Neoplasia/genética , Metástasis de la Neoplasia/patología , Terapia de Reemplazo de Hormonas/métodos , Terapia de Reemplazo de Hormonas/normas , Calidad de Vida/psicología , Preparaciones Farmacéuticas/administración & dosificación , Preparaciones Farmacéuticas/metabolismo , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/radioterapia , Metástasis de la Neoplasia/tratamiento farmacológico , Metástasis de la Neoplasia/terapia , Terapia de Reemplazo de Hormonas/psicología , Terapia de Reemplazo de Hormonas , Supervivencia/fisiología , Preparaciones Farmacéuticas , Preparaciones Farmacéuticas/provisión & distribuciónRESUMEN
Androgen deprivation treatment is the current standard first-line treatment for metastatic prostate cancer. For several years, docetaxel was the only treatment with a proven survival benefit for castration-resistant prostate cancer (CRPC). Since docetaxel became standard of care for men with symptomatic metastatic castration-resistant prostate cancer (CRPC), three treatment virtual spaces, for treatment and drug development in CPRC, have emerged: pre-docetaxel, docetaxel combinations and post-docetaxel. Sipuleucel-T, cabazitaxel, abiraterone, enzalutamide and radium-223 have been approved in the pre- or post-docetaxel setting in metastatic CRPC during the last few years. Patients are now living longer and experiencing better quality of life. Strategies for patient selection and treatment sequencing are therefore urgently require (AU)
No disponible
Asunto(s)
Humanos , Masculino , Neoplasias de la Próstata/diagnóstico , Neoplasias de la Próstata/tratamiento farmacológico , Andrógenos/uso terapéutico , Antineoplásicos/uso terapéutico , Neoplasias de la Próstata/fisiopatología , Neoplasias de la Próstata , Castración/tendenciasRESUMEN
Background. Malnutrition is a frequent medical problem of cancer patients that negatively impacts their quality of life. Methods. A multidisciplinary group of experts in Medical Oncology, Pharmacy, and Nutrition convened to discuss the management of the nutritional support in cancer patients. Results. Of the 18 questions addressed, 9 focused on nutritional support, 5 were related to parenteral nutrition (PN) and 4 about home PN (HPN). The panel of experts recommends using nutritional screening routinely, at diagnosis and throughout the disease course, for detecting the risk of malnutrition and, if it is positive, to perform a complete nutritional assessment, to diagnose malnutrition. Currently, there are different screening tools and methods that allow us to detect nutritional risk. Based on the evidence and experience, the panel stated that PN is indicated mainly when it is not possible to use the digestive tract and/or oral feeding and/or enteral nutrition is not sufficient or possible. The nutritional needs of the cancer patients, except in those cases where individualized measures are required, should be considered similar to healthy individuals (25-30 kcal/kg/day). The panel considers that the nutritional monitoring of the cancer patient should be multidisciplinary and adapted to the characteristics of each center. Additionally, the objective of the HPN is to improve or maintain the nutritional status of a patient at home. Conclusions. This document seeks to lay down a set of recommendations and to identify key issues that may be useful for the nutritional management of cancer patients
No disponible
Asunto(s)
Humanos , Desnutrición/etiología , Desnutrición/terapia , Neoplasias/complicaciones , Apoyo Nutricional/métodos , Nutrición Enteral , Nutrición Parenteral Total en el DomicilioRESUMEN
Despite the fact that thromboembolism is relatively common in oncology patients and that the interrelationship between thrombotic risk and specific mechanisms of tumorigenesis has long been known, many cardinal elements of prevention and treatment remain unresolved. Among the existing knowledge gaps, the need to validate the Ay scale and compare it to the Khorana index, develop, and standardize the use of predictive biomarkers for thrombotic risk, conduct clinical trials in thromboprophylaxis adapted to thrombotic risk, evaluate the efficacy and safety of direct anticoagulants, select patients who can benefit from anticoagulants for antitumor treatment, validate the EPIPHANY study decision tree to choose patients with low-risk pulmonary embolism, and accumulate more practical experience in special situations (rethrombosis, prolonged therapy beyond 6 months, etc.) are especially remarkable. These gray areas surrounding cancer-related thromboembolism explain why it continues to be a relatively common cause of serious events, at times interfering significantly with the development of new tumor-fighting strategies (AU)
No disponible
Asunto(s)
Humanos , Trombosis/complicaciones , Neoplasias/complicaciones , Trombosis/prevención & control , Trombocitopenia/diagnóstico , Biomarcadores/análisis , Factores de RiesgoRESUMEN
Purpose. Long-term cancer survivors develop special health issues and specific needs. Chronic pain, whether the consequence of their cancer or as a side effect of treatment, is one of their most prevalent concerns. Methods. We conducted a review of the English-language literature on long-term cancer survivorship and chronic opioid therapy, with the objective of determining the efficacy, safety and tolerability in this group of patients. Practical management recommendations are made on the basis of this review. Results. Pain syndromes encountered in the long-term cancer survivors are diverse. Opioid receptor pathways possess complex and pleiotropic functions and continuous over-activation may lead to de novo endocrinopathies, immunosuppression, neurocognitive impairment, or cell cycle disturbances with potential clinical connotations. However, there are insufficient data to support evidence-based decision making with respect to patient selection, doses, administration, monitoring and follow-up. Data about long-term treatment effectiveness and safety are limited and often aggravated by the overlapping of several diseases prevalent among long-term cancer survivors, as well as chronic opiate-induced toxicity. Conclusions. Chronic opioid therapy is frequent in long-term cancer survivors, and may negatively affect the immune system, and produce health problems such as endocrinopathies, osteoporosis, neurological or cardiopulmonary effects, alterations of cell cycle kinetics, abuse and addiction. This review highlights the need for specialized teams to treat chronic pain in long-term cancer survivors from an integrative perspective (AU)
No disponible
Asunto(s)
Humanos , Masculino , Femenino , Neoplasias/tratamiento farmacológico , Antagonistas de Narcóticos/uso terapéutico , Dolor Crónico/tratamiento farmacológico , Analgésicos Opioides/uso terapéutico , Sobrevida , Resultado del Tratamiento , Hipogonadismo/complicacionesRESUMEN
An expert group from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC, for its acronym in Spanish) and the Spanish Society of Medical Oncology (SEOM, for its acronym in Spanish) have reviewed the main aspects to be considered when evaluating patients with solid cancer and infectious complications contained in this article. Recommendations have, therefore, been put forth regarding the prophylaxis of the most prevalent infections in these patients, the use of vaccines, measures to control infection through vascular catheters, and preventing infection in light of certain surgical maneuvers. The following is a revision of the criteria for febrile neutropenia management and the use of colonystimulating factors and closes with several guidelines for treating the cancer patient with serious infection. The document concludes with a series of measures to control hospital infection (AU)
No disponible
Asunto(s)
Humanos , Masculino , Femenino , Neutropenia Febril/complicaciones , Neutropenia Febril/tratamiento farmacológico , Criterios de Evaluación de Respuesta en Tumores Sólidos , Factores de Riesgo , Hepatitis B/complicaciones , Hepatitis B/tratamiento farmacológico , Hepatitis B/inmunología , Factor Estimulante de Colonias de Granulocitos , Factor Estimulante de Colonias de Granulocitos/inmunología , Control de Infecciones/métodos , Vacunación/tendencias , Profilaxis Antibiótica/instrumentación , Profilaxis Antibiótica/métodos , Profilaxis Antibiótica , Pneumocystis carinii , Pneumocystis carinii/aislamiento & purificaciónRESUMEN
Cancer pain should be controlled in most patients, however this is not always achieved. These guidelines describe the classification, evaluation and treatment of chronic cancer pain in accordance with the WHO treatment strategy of pain stages: mild, moderate and severe. For treatment during the third stage, we cover titration and rotation of opioids, as well as their side effects and prevention. Also described is neuropathic pain and refractory pain, coadjuvant treatments and non pharmacological analgesic treatments. Finally, treatment of breakthrough pain is defined (AU)